新型促骨形成剂Abaloparatide的研究进展  

Abaloparatide: research progress of a new anabolic agent for osteoporosis

作　　者：侯艳芳 刘建民[1] HOU Yan-fang;LIU Jian-min(Department of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China)

机构地区：[1]上海交通大学医学院附属瑞金医院内分泌代谢科上海市内分泌代谢病临床医学中心上海市内分泌代谢病研究所,上海200025

出　　处：《中华骨质疏松和骨矿盐疾病杂志》2018年第3期290-295,共6页Chinese Journal Of Osteoporosis And Bone Mineral Research

摘　　要：Abaloparatide(TymlosTM)是一种新合成的甲状旁腺素相关肽(human parathyroid hormone-related protein,PTHr P)类似物,2017年4月被美国食品和药物管理局批准用于绝经后女性骨质疏松症的治疗。它可选择性作用于甲状旁腺素受体1的RG构象,使其促进骨形成的能力超过骨吸收。研究表明,每日皮下注射Abaloparatide 80μg不仅能显著提高腰椎骨密度(bone mineral density,BMD),还可以提高髋部和股骨颈BMD,显著降低椎体和非椎体骨折风险,具有相对低的高钙血症的发生率。本文将从Abaloparatide的药代动力学、作用机制、其在OP中的作用及治疗剂量和不良反应等方面作一综述。Abaloparatide （ TymlosTM） is a synthetic peptide analogue of human parathyroid hormone-related protein that received its first global approval in the USA for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Abaloparatide can selectively bind to the RG conformation of the parathyroid hormone type 1 re-ceptor （ PTHR1） which may result in greater stimulation of bone formation than resorption. Clinical studies suggested that subcutaneous abaloparatide 80 μg once daily could reduce the risk of vertebral and non-vertebral fractures. It can significantly increase not only lumbar-spine bone mineral density （ BMD） , but also total hip and femoral neck BMD. Abaloparatide also has lower incidence of hypercalcemia. This review described the pharmacokinetics, the mechanism and effect on osteoporosis, the dosage and side effect of Abaloparatide.

关 键 词：Abaloparatide 骨质疏松 甲状旁腺素相关肽 

分 类 号：R681[医药卫生—骨科学]